

# Calcineurin Inhibitor Sparing in Renal Transplantation

Transplantation

86, 761-767

DOI: [10.1097/tp.0b013e3181856f39](https://doi.org/10.1097/tp.0b013e3181856f39)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Mycophenolate Mofetil and Calcineurin-Inhibitor Reduction: Recent Progress. American Journal of Transplantation, 2009, 9, 2447-2452.	4.7	33
2	Effect of conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium on maximum tolerated dose and gastrointestinal symptoms following kidney transplantation. Transplant International, 2009, 22, 821-830.	1.6	34
3	Refining the definition and management of high-risk organ transplant recipients. Current Opinion in Organ Transplantation, 2009, 14, 634-635.	1.6	0
4	Calcineurin Inhibitor-Based Immunosuppressive Therapy, Donor Age, and Long-Term Outcome After Kidney Transplantation. Transplantation, 2009, 87, 1821-1829.	1.0	8
5	Everolimus With Reduced Calcineurin Inhibitor in Thoracic Transplant Recipients With Renal Dysfunction: A Multicenter, Randomized Trial. Transplantation, 2010, 89, 864-872.	1.0	126
7	Exogenous Interferon- $\gamma$ Immunotherapy for Invasive Fungal Infections in Kidney Transplant Patients. American Journal of Transplantation, 2010, 10, 1796-1803.	4.7	91
8	Long-Term Impact of Cyclosporin Reduction with MMF Treatment in Chronic Allograft Dysfunction: REFERENCE Study 3-Year Follow Up. Journal of Transplantation, 2010, 2010, 1-11.	0.5	9
9	BH3 mimetics antagonizing restricted prosurvival Bcl-2 proteins represent another class of selective immune modulatory drugs. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 10967-10971.	7.1	97
10	Sirolimus-Induced Isometric Tubular Vacuolization: A New Sirolimus Histopathologic Manifestation. Transplantation Proceedings, 2010, 42, 2547-2550.	0.6	9
11	Impact of IL2 and IL2RB Genetic Polymorphisms in Kidney Transplantation. Transplantation Proceedings, 2011, 43, 2383-2387.	0.6	10
12	Selective Depletion of Cross-Presenting Dendritic Cells Enhances Islet Allograft Survival. Cell Transplantation, 2011, 20, 467-474.	2.5	9
13	Mycophenolate Mofetil Initiation in Renal Transplant Patients at Different Times Posttransplantation: The TranCept Switch Study. Transplantation, 2011, 91, 984-990.	1.0	9
14	Calcineurin inhibitor sparing regimens using m-target of rapamycin inhibitors: an opportunity to improve cardiovascular risk following kidney transplantation?. Transplant International, 2011, 24, 30-42.	1.6	34
15	Y-Box Binding Protein-1 Mediates Profibrotic Effects of Calcineurin Inhibitors in the Kidney. Journal of Immunology, 2011, 187, 298-308.	0.8	37
16	Mycophenolate mofetil maintenance therapy in renal transplant patients: long-term results of the <sc>T</sc>ran<sc>C</sc>ept <sc>STAY</sc> study. Clinical Transplantation, 2012, 26, 919-926.	1.6	9
17	A high-throughput U-HPLC-MS/MS assay for the quantification of mycophenolic acid and its major metabolites mycophenolic acid glucuronide and mycophenolic acid acyl-glucuronide in human plasma and urine. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 883-884, 113-119.	2.3	38
18	A Prospective, Multinational Pharmacoepidemiological Study of Clinical Conversion to Sirolimus Immunosuppression after Renal Transplantation. Journal of Transplantation, 2012, 2012, 1-16.	0.5	6
19	Improved Renal Function After Early Conversion From a Calcineurin Inhibitor to Everolimus: a Randomized Trial in Kidney Transplantation. American Journal of Transplantation, 2012, 12, 2744-2753.	4.7	86

#	ARTICLE	IF	CITATIONS
20	Enteric-coated mycophenolate sodium in <i>de novo</i> and maintenance kidney-pancreas transplant recipients. <i>Clinical Transplantation</i> , 2012, 26, 424-431.	1.6	4
21	Immunosuppressive properties of a series of novel inhibitors of the monocarboxylate transporter MCT-1. <i>Transplant International</i> , 2013, 26, 22-29.	1.6	37
22	Influence of SLCO1B3 Genetic Variations on Tacrolimus Pharmacokinetics in Renal Transplant Recipients. <i>Drug Metabolism and Pharmacokinetics</i> , 2013, 28, 274-277.	2.2	22
23	ELEVATE: an innovative study design to assess the efficacy, safety, and evolution of cardiovascular parameters in de novo kidney transplant recipients after early conversion from a calcineurin inhibitor to everolimus. <i>Open Access Journal of Clinical Trials</i> , 2014, , 17.	1.5	2
24	Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial. <i>Lancet, The</i> , 2014, 384, 1684-1690.	13.7	124
25	Enhancement of CD147 on M1 macrophages induces differentiation of Th17 cells in the lung interstitial fibrosis. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2014, 1842, 1770-1782.	3.8	17
26	Renal function three years after early conversion from a calcineurin inhibitor to everolimus: results from a randomized trial in kidney transplantation. <i>Transplant International</i> , 2015, 28, 42-51.	1.6	37
27	Pharmacokinetic Analysis of Mycophenolate Mofetil and Enteric-Coated Mycophenolate Sodium in Calcineurin Inhibitor-free Renal Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 388-392.	2.0	6
28	The epoxyeicosatrienoic acid analog PVPA ameliorates cyclosporine-induced hypertension and renal injury in rats. <i>American Journal of Physiology - Renal Physiology</i> , 2016, 311, F576-F585.	2.7	17
29	The efficacy and safety of intensified enteric-coated mycophenolate sodium with low exposure of calcineurin inhibitors in Chinese de novo kidney transplant recipients: a prospective study. <i>International Journal of Clinical Practice</i> , 2016, 70, 22-30.	1.7	6
30	Overview of Immunosuppressive Therapy in Solid Organ Transplantation. <i>Anesthesiology Clinics</i> , 2017, 35, 365-380.	1.4	73
31	Campath, calcineurin inhibitor reduction, and chronic allograft nephropathy (the 3C Study) - results of a randomized controlled clinical trial. <i>American Journal of Transplantation</i> , 2018, 18, 1424-1434.	4.7	18
32	Clinical Study of Standard- vs Reduced-Dose Tacrolimus Combined With Generic Mycophenolate Mofetil in De Novo Kidney Transplantation: A Prospective Randomized Trial. <i>Transplantation Proceedings</i> , 2020, 52, 133-139.	0.6	0
33	Involvement of heme oxygenase-1 in suppression of T cell activation by quercetin. <i>Immunopharmacology and Immunotoxicology</i> , 2020, 42, 295-305.	2.4	3
34	Calcineurin inhibitor sparing strategies in renal transplantation, part one: Late sparing strategies. <i>World Journal of Transplantation</i> , 2014, 4, 57.	1.6	15
35	Treatment of De Novo Renal Transplant Recipients With Calcineurin Inhibitor-free, Belatacept Plus Everolimus-based Immunosuppression. <i>Transplantation Direct</i> , 2023, 9, e1419.	1.6	1